Prescient Therapeutics (UDD) Stock Overview

A clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. More details

UDD fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings have declined by 15.6% per year over past 5 years

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

Does not have meaningful revenue (A$4M)

+ 1 more risk

UDD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW479,582 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

479,582 investors already sharing narratives

View all narratives

Prescient Therapeutics Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Prescient Therapeutics
Historical stock prices
Current Share Price	AU$0.038
52 Week High	AU$0.06
52 Week Low	AU$0.026
Beta	0.73
1 Month Change	31.03%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-64.49%
Change since IPO	-99.85%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	UDD	DE Biotechs	DE Market
7D	4.1%	-0.1%	0.1%
1Y	n/a	11.4%	-0.5%

Return vs Industry: Insufficient data to determine how UDD performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how UDD performed against the German Market.

Price Volatility

Is UDD's price volatile compared to industry and market?
UDD volatility
UDD Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.7%
Market Average Movement	5.3%
10% most volatile stocks in DE Market	12.7%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: UDD's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine UDD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1986	n/a	James McDonnell	ptxtherapeutics.com

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014.

Prescient Therapeutics Limited Fundamentals Summary

How do Prescient Therapeutics's earnings and revenue compare to its market cap?
UDD fundamental statistics
Market cap	€50.27m
Earnings (TTM)	-€5.43m
Revenue (TTM)	€2.61m

19.2x

P/S Ratio

-9.3x

P/E Ratio

Is UDD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UDD income statement (TTM)
Revenue	AU$4.27m
Cost of Revenue	AU$0
Gross Profit	AU$4.27m
Other Expenses	AU$13.13m
Earnings	-AU$8.86m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0084
Gross Margin	100.00%
Net Profit Margin	-207.71%
Debt/Equity Ratio	0%

How did UDD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/22 20:54
End of Day Share Price	2026/07/22 00:00
Earnings	2025/12/31
Annual Earnings	2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Prescient Therapeutics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Paul Hickman	Edison Investment Research